12
38
Growth Score
3 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
439627
Cessation Therapeutics provides therapeutics for an addiction-free through immunotherapy-based biotech innovation.
- David Genecov: Chief Medical Officer, Co-Founder and Director
- Mark Pearson: Co-Founder and Chairman
About the Company
Cessation Therapeutics provides therapeutics for an addiction-free through immunotherapy-based biotech innovation.
Cessation Therapeutics is developing novel immunotherapy vaccine candidates and small molecules with the objective of helping millions of families overcome the opioid, heroin, morphine, fentanyl, alcohol and nicotine addiction use
disorders. Cessation Therapeutics is currently developing heroin, opioid and fentanyl addiction vaccines based on the technology licensed from The Scripps Research Institute in La Jolla, California (TSRI) and has commenced planning pre-clinical studies to advance these vaccine candidates into clinical stage.
